非处方助听器自我验配策略比较:一项交叉临床试验
这项交叉临床试验纳入28名轻度至中度听力困难的成人,比较自我调整与原位测听两种非处方自验配助听器策略,各使用4周。结果显示两种策略在助听器获益(Cohen d=0.2;95%CI,-0.2至0.6)和满意度(Rosenthal r=0.0;95%CI,-0.3至0.2)上无临床意义差异,但自我调整组报告更高满意度和更长每日使用时间。
要点
- 自我调整与原位测听策略在助听器获益上无临床意义差异(Cohen d=0.2;95%CI,-0.2至0.6)。
- 自我调整组满意度更高(Rosenthal r=-0.4;95%CI,-0.6至-0.1)且每日使用时间更长(Rosenthal r=-0.3;95%CI,-0.5至0.0)。
- 两种策略在噪声下言语获益和真耳测量上无临床意义差异。
核心结论
- 在非处方自验配助听器中,自我调整与原位测听策略产生相似结果,但自我调整可能带来更高满意度和更长每日使用时间,突显主动用户参与验配过程的潜在优势。
- 需要进一步研究长期结果。
研究设计与样本
- 交叉、受试者内伪随机化临床试验,于2023年7月至11月开展。
- 28名轻度至中度听力困难的成人被伪随机分配至两种自我验配策略之一,并连续4周体验两种干预。
- 自我调整组使用Lexie B2助听器手动调整设置(包括总增益和频谱倾斜),原位测听组使用Lexie B2 Plus助听器(Lexie Hearing by hearX Group),通过应用程序进行原位测试并自动验配。
- 主要结局为简明助听器获益简档(APHAB),次要结局包括国际助听器效果量表(IOI-HA)、噪声下言语测试(DIN和QuickSIN)及真耳测量(REMs)。
- 在基线和每种策略4周现场试验后完成测量。
主要发现
- 共纳入28名参与者(平均[SD]年龄60.2[12.0]岁),男14名、女14名。
- 自我调整与原位测听策略在多项结局指标上无临床意义差异,包括总体APHAB获益(Cohen d=0.2;95%CI,-0.2至0.6)和总体IOI-HA满意度(Rosenthal r=0.0;95%CI,-0.3至0.2)。
- 与使用原位测听的参与者相比,自我调整使用者报告更高满意度(Rosenthal r=-0.4;95%CI,-0.6至-0.1)和更长每日使用时间(Rosenthal r=-0.3;95%CI,-0.5至0.0)。
- 在噪声下言语获益和真耳测量中未观察到临床意义差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究长期结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Fewer than 20% of US adults with hearing loss use hearing aids due to barriers like high cost. Over-the-counter (OTC) hearing aids offer a potential solution, incorporating self-fitting strategies via smartphone apps. Self-fitting strategies have been validated for Food and Drug Administration (FDA)-approved OTC hearing aids compared with prescription-based approaches. However, no direct comparative analysis exists between in situ audiometry and self-adjustment strategies using self-fitting OTC (OTC-SF) hearing aids. OBJECTIVE: To compare self-adjustment and in situ audiometry self-fitting strategies in OTC-SF hearing aids for adults with mild to moderate hearing difficulties. DESIGN SETTINGS AND PARTICIPANTS: A crossover, within-participant pseudorandomized clinical trial was conducted between July and November 2023. Twenty-eight participants were pseudo-randomly assigned to 1 of the 2 self-fitting strategies, and they experienced both interventions for 4 consecutive weeks. INTERVENTIONS: The self-adjustment group manually adjusted settings, including overall gain and spectral tilt, using Lexie B2 hearing aids, while the in situ audiometry group used Lexie B2 Plus hearing aids (Lexie Hearing by hearX Group), with an automated fitting based on in situ tests conducted through the app. MAIN OUTCOMES AND MEASURES: The primary outcome was Abbreviated Profile of Hearing Aid Benefit (APHAB). Secondary outcomes were International Outcome Inventory for Hearing Aids (IOI-HA), speech-in-noise tests (DIN and QuickSIN), and real-ear measurements (REMs). Measures were completed at baseline and after the 4-week field trial using each strategy. RESULTS: Twenty-eight participants (mean [SD] age, 60.2 [12.0] years) were included; 14 men and 14 women. Self-adjustment and in situ audiometry strategies produced no clinically meaningful differences across various outcome measures, including overall APHAB benefit (Cohen d = 0.2; 95% CI, -0.2 to 0.6) and overall IOI-HA satisfaction (Rosenthal r = 0.0; 95% CI, -0.3 to 0.2). Self-adjustment users reported higher satisfaction (Rosenthal r = -0.4; 95% CI, -0.6 to -0.1) and longer daily use (Rosenthal r = -0.3; 95% CI, -0.5 to 0.0) compared with those using in situ audiometry. No clinically meaningful differences were observed in speech-in-noise benefit and real-ear measurements. CONCLUSION AND RELEVANCE: In this clinical trial of OTC-SF hearing aids, self-adjustment and in situ audiometry strategies resulted in similar outcomes. However, self-adjustment may produce higher satisfaction and longer daily use, highlighting the potential advantages of active user involvement in the fitting process. Further investigation is needed for long-term outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05782153.
引用
- Knoetze M, Manchaiah V, De Sousa K, et al. Comparing Self-Fitting Strategies for Over-the-Counter Hearing Aids: A Crossover Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 39052241. doi:10.1001/jamaoto.2024.2007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。